Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
The latest update is out from InfuSystem Holdings ( (INFU) ).
InfuSystem Holdings reported six consecutive years of record revenue, with a compound annual growth rate of 12% in revenue and 11% in adjusted EBITDA. The company announced various strategic partnerships and distribution agreements in recent years, enhancing its market position and expanding its service offerings in areas like wound care and biomedical services.
The most recent analyst rating on (INFU) stock is a Hold with a $10.50 price target. To see the full list of analyst forecasts on InfuSystem Holdings stock, see the INFU Stock Forecast page.
Spark’s Take on INFU Stock
According to Spark, TipRanks’ AI Analyst, INFU is a Neutral.
InfuSystem Holdings shows strong financial performance with significant revenue growth and strategic initiatives in Oncology and Wound Care. However, the stock is currently overvalued, and challenges in certain revenue streams pose risks. Technical indicators suggest mixed momentum, with short-term bearish signals but longer-term positive trends.
To see Spark’s full report on INFU stock, click here.
More about InfuSystem Holdings
InfuSystem Holdings is a leading provider of medical equipment and patient services in the U.S. and Canada, with nearly four decades of experience. The company has a significant presence in oncology therapy and is expanding into other therapies. It serves a wide range of healthcare facilities and insurance networks, providing device solutions and patient services.
Average Trading Volume: 244,426
Technical Sentiment Signal: Buy
Current Market Cap: $212.1M
For an in-depth examination of INFU stock, go to TipRanks’ Overview page.